Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Hospitalier Universitaire de Nīmes
Brain mapping of COVID-19 patients with or without anosmia will allow better understanding of the mechanisms leading to the onset of these symptoms and will provide a pathophysiological basis for the therapeutic interventions to improve the clinical prognosis of affected patients.
The study investigators hypothesize that in COVID-19 patients witch anosmia the brain mapping objectified by an MRI examination is modified and that there are functional abnormalities in the brain in these patients.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Consecutive adult patients consulting the CAREB or hospitalized at the Nîmes teaching hospital due to COVID-19 infection (fever, persistent cough, tiredness, shortness of breath, diarrhea, abdominal pain, chest pain, sore throat, loss of smell or taste)
COVID-19 confirmed by RT-PCR and / or chest CT or clinical characteristics (i.e an epidemic history and 2 clinical manifestations or at least 3 clinical manifestations)
The patient must have given their free and informed consent and signed the consent form
The patient must be a member or beneficiary of a health insurance plan "with anosmia" group:
scoring \< 30 on a VAS 0-100 for olfactory ability
Responding "yes" to question "have you lost your sense of smell in the last few days?"
Negative result to olfactory test with n-Butanol diluted to 1/1000. "without anosmia" group:
scoring \< 80 on a VAS 0-100 for olfactory ability
Responding "no" to question "have you lost your sense of smell in the last few days?"
Positive result to olfactory test with n-Butanol diluted to 1/16000.
You may not be if
Patient suffering from serious medical problems or hospitalized in an intensive care unit for invasive ventilation or severe dyspnea.
Patient with neurological (motor, sensitive or cognitive), neuropsychiatric or vascular disorders.
Patient with a contraindication to MRI (pace maker, claustrophobic patient, metallic heart valve, etc.).
Patient with a history of rhinological pathology or a sense of smell problem.
Patient with known neurological, psychiatric or neuroradiological manifestation.The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study
The subject is unable to express consent
It is impossible to give the subject informed information
The patient is under safeguard of justice or state guardianship
